<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/74F2A1AB-3E8C-4E93-AA79-60C113D8EC01"><gtr:id>74F2A1AB-3E8C-4E93-AA79-60C113D8EC01</gtr:id><gtr:name>Glide Pharmaceutical Technologies Limited</gtr:name><gtr:address><gtr:line1>45B WESTERN AVENUE , MILTON PARK</gtr:line1><gtr:city>ABINGDON</gtr:city><gtr:postCode>OX14 4RU</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/74F2A1AB-3E8C-4E93-AA79-60C113D8EC01" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>74F2A1AB-3E8C-4E93-AA79-60C113D8EC01</gtr:id><gtr:name>Glide Pharmaceutical Technologies Limited</gtr:name><gtr:address><gtr:line1>45B WESTERN AVENUE , MILTON PARK</gtr:line1><gtr:city>ABINGDON</gtr:city><gtr:postCode>OX14 4RU</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>2285252.0</gtr:offerGrant><gtr:projectCost>3811428.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8E7DCF78-CB56-457F-9BCF-DB1F614C3241"><gtr:id>8E7DCF78-CB56-457F-9BCF-DB1F614C3241</gtr:id><gtr:firstName>Jon</gtr:firstName><gtr:surname>Telfer</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=101366"><gtr:id>C242359B-1B13-4788-8919-2C6324886235</gtr:id><gtr:title>Novel Teriparatide (PTH) Formulation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>101366</gtr:grantReference><gtr:abstractText>Osteoporosis is a debilitating disease. About 55% of people over 50 are at risk of developing osteoporosis, with post-menopausal women at greatest risk. Osteoporosis affects 2 million people in the UK and 70,000 suffer hip fractures (among the worst in the EU). Treatment of hip fracture alone costs the NHS &amp;pound;2bn annually. Teriparatide (PTH) is currently the most effective medical intervention. Daily PTH injection has resulted in a 66-90% decrease in vertebral fractures and about a 50% drop in non-vertebral fractures. However, the current PTH product must be stored under refrigerated conditions. Whilst most bone physicians believe that PTH is a good drug, few actually prescribe it as its use is very restrictive in terms of travel and work, over a long treatment time (24 months) as well as the high cost. The aim of this project is to develop a generic version of PTH that is cost effective and can be used by patients &amp;quot;on the go&amp;quot; by use of the patented, needle free, Glide SDI&amp;reg; technology.</gtr:abstractText><gtr:fund><gtr:end>2015-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2285252</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">101366</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>